S2Medical AB is a Swedish biomed-tech company that develops products and technologies for wound healing, infection control, and cosmeceuticals. The company utilizes biomaterials, regenerative medicine, and antimicrobial peptides to create solutions such as negative pressure therapy systems and treatments for multi-resistant bacterial infections, serving patients and healthcare providers.
Subscribe to see S2Medical B’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
S2Medical B is a health care company headquartered in Sweden. Xcout tracks 2 named people at S2Medical B, including Petter Sivlér (CEO, Co-Founder MSc Bio Med, PhD. Cand.).
A few of S2Medical B's closest competitors — see the full list of competitors and alternatives →
SolasCure Limited is a biotechnology research company registered and headquartered in Cambridge, United Kingdom, focused on developing novel wound care solutions.
Amferia is a Swedish biotechnology company specializing in antimicrobial wound-care solutions using bio-inspired peptides. Founded in Gothenburg, the company operates a clinical production site in Mölndal for testing and evaluating its healthcare products.
Tiger Biotherapeutics Inc. is a regenerative medicine company that develops and provides advanced cellular, acellular, and matrix-like products (CAMPs) for wound care, aesthetics, and tissue science. The company serves healthcare providers and patients by offering solutions for tissue repair, wound closure, and reconstructive or cosmetic applications.
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.